Composition of Total Revenue

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Composition of Total Revenue

COMPOSITION OF TOTAL REVENUE

The below table presents our net product sales by geography for the years ended December 31, 2016, 2015, and 2014:

	Year Ended December 31,
	2016				2015				2014
United States	$	125,074	97.3	%	$	130,432	95.3	%	$	177,979	95.4	%
International:
Europe	3,522		2.7	%	2,234		1.6	%	3,357		1.8	%
Asia Pacific*	—		—	%	4,185		3.1	%	5,201		2.8	%
Total International	3,522		2.7	%	6,419		4.7	%	8,558		4.6	%
Net product sales	$	128,596	100	%	$	136,851	100.0	%	$	186,537	100.0	%

* See Note 12 for discussion of our November 2015 out-license for the Asia Pacific territory to Mundipharma.

The below table presents our net product sales by drug for the years ended December 31, 2016, 2015, and 2014:

	Year Ended December 31,
	2016				2015				2014
FUSILEV	$	34,839	27.1	%	$	60,710	44.4	%	$	105,608	56.6	%
FOLOTYN	46,245		36.0	%	40,606		29.7	%	47,556		25.5	%
ZEVALIN	10,730		8.3	%	17,457		12.8	%	22,169		11.9	%
MARQIBO	7,245		5.6	%	8,006		5.9	%	6,328		3.4	%
BELEODAQ	13,368		10.4	%	10,072		7.4	%	4,876		2.6	%
EVOMELA	16,169		12.6	%	—		—	%	—		—	%
Net product sales	$	128,596	100.0	%	$	136,851	100.0	%	$	186,537	100.0	%

The below table presents our license fees and service revenue by source for the years ended December 31, 2016, 2015, and 2014:

	Year Ended December 31,
	2016				2015				2014
Out-license of ZEVALIN, FOLOTYN, BELEODAQ, MARQIBO: upfront receipt for the Canada territory (Note 17(b)(xiv))	$	6,000	33.6	%	$	—	—	%	$	—	—	%
Sales and marketing contracted services (Note 14)	9,096		51.0	%	—		—	%	—		—	%
Out-license of ZEVALIN: upfront receipts and royalties for Asia and certain other territories, excluding China (Note 12)	1,756		9.8	%	15,144		58.9	%	—		—	%
Out-license of FOLOTYN in all countries except the U.S., Canada, Europe, and Turkey (Note 16)	927		5.2	%	831		3.2	%	293		100.0	%
Out-license of ZEVALIN, MARQIBO, EVOMELA: upfront receipt for the China territory (Note 11)	—		—	%	9,682		37.7	%	—		—	%
Out-license of ZEVALIN: amortization of upfront receipt related to India territory (Note17(b)(iii)) and other	69		0.4	%	48		0.2	%	—		—	%
License fees and service revenues	$	17,848	100.0	%	$	25,705	100.0	%	$	293	100.0	%